The findings suggest that MsA provides multi-target neuroprotection against AD’s key pathologies: amyloid plaques, neurofibrillary tangles, cholinergic degeneration, and oxidative stress, via the PI3K/AKT/GSK3β/CREB signaling pathway. Here, CREB1 is linked to Alzheimer disease.